Literature DB >> 33641864

The Microenvironment in Myeloproliferative Neoplasms.

Gajalakshmi Ramanathan1, Angela G Fleischman2.   

Abstract

Chronic inflammation is a hallmark of myeloproliferative neoplasms (MPNs), with elevated levels of proinflammatory cytokines being commonly found in all 3 subtypes. Systemic inflammation is responsible for the constitutional symptoms, thrombosis risk, premature atherosclerosis, and disease evolution in MPN. Although the neoplastic clone and their differentiated progeny drive the inflammatory process, they also induce ancillary cytokine secretion from nonmalignant cells. Here, the authors describe the inflammatory milieu in MPN based on soluble factors and cellular mediators. They also discuss the prognostic value of cytokine measurements in patients with MPN and potential therapeutic strategies that target the cellular players in inflammation.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokines; Inflammation; Microenvironment; Myeloid cells; Myeloproliferative neoplasm; Prognosis

Mesh:

Substances:

Year:  2020        PMID: 33641864      PMCID: PMC8832361          DOI: 10.1016/j.hoc.2020.11.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  56 in total

1.  Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

Authors:  Tiziano Barbui; Alessandra Carobbio; Guido Finazzi; Alessandro M Vannucchi; Giovanni Barosi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Pancrazzi; Silvia Salmoiraghi; Pio Zilio; Cosimo Ottomano; Roberto Marchioli; Ivan Cuccovillo; Barbara Bottazzi; Alberto Mantovani; Alessandro Rambaldi
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

2.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

3.  Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.

Authors:  Lorena Arranz; Abel Sánchez-Aguilera; Daniel Martín-Pérez; Joan Isern; Xavier Langa; Alexandar Tzankov; Pontus Lundberg; Sandra Muntión; Yi-Shiuan Tzeng; Dar-Ming Lai; Jürg Schwaller; Radek C Skoda; Simón Méndez-Ferrer
Journal:  Nature       Date:  2014-06-22       Impact factor: 49.962

4.  Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders.

Authors:  K L Bourantas; E C Hatzimichael; A C Makis; A Chaidos; E D Kapsali; S Tsiara; A Mavridis
Journal:  Eur J Haematol       Date:  1999-07       Impact factor: 2.997

5.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Authors:  Ayalew Tefferi; Rakhee Vaidya; Domenica Caramazza; Christy Finke; Terra Lasho; Animesh Pardanani
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

6.  Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications.

Authors:  Emmanuel Pourcelot; Candice Trocme; Julie Mondet; Sébastien Bailly; Bertrand Toussaint; Pascal Mossuz
Journal:  Exp Hematol       Date:  2014-01-23       Impact factor: 3.084

7.  Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.

Authors:  Ofir Wolach; Rob S Sellar; Kimberly Martinod; Deya Cherpokova; Marie McConkey; Ryan J Chappell; Alexander J Silver; Dylan Adams; Cecilia A Castellano; Rebekka K Schneider; Robert F Padera; Daniel J DeAngelo; Martha Wadleigh; David P Steensma; Ilene Galinsky; Richard M Stone; Giulio Genovese; Steven A McCarroll; Bozenna Iliadou; Christina Hultman; Donna Neuberg; Ann Mullally; Denisa D Wagner; Benjamin L Ebert
Journal:  Sci Transl Med       Date:  2018-04-11       Impact factor: 17.956

Review 8.  Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis.

Authors:  Milka Koupenova; Lauren Clancy; Heather A Corkrey; Jane E Freedman
Journal:  Circ Res       Date:  2018-01-19       Impact factor: 17.367

9.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

10.  Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study.

Authors:  F Murphy; M E Kroll; K Pirie; G Reeves; J Green; V Beral
Journal:  Br J Cancer       Date:  2013-05-02       Impact factor: 7.640

View more
  4 in total

1.  Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.

Authors:  Vibe Skov; Mads Thomassen; Lasse Kjær; Christina Ellervik; Morten Kranker Larsen; Trine Alma Knudsen; Torben A Kruse; Hans C Hasselbalch
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

2.  The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry.

Authors:  Chris Varghese; Tracey Immanuel; Anna Ruskova; Edward Theakston; Maggie L Kalev-Zylinska
Journal:  Curr Oncol       Date:  2021-04-18       Impact factor: 3.677

Review 3.  JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation.

Authors:  Garima Pandey; Andrew T Kuykendall; Gary W Reuther
Journal:  Blood Cancer J       Date:  2022-01-26       Impact factor: 11.037

Review 4.  Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.

Authors:  Maria Teresa Bochicchio; Valeria Di Battista; Pietro Poggio; Giovanna Carrà; Alessandro Morotti; Mara Brancaccio; Alessandro Lucchesi
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.